Barclays PLC Buys 73,127 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

Barclays PLC boosted its stake in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) by 189.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 111,666 shares of the company’s stock after purchasing an additional 73,127 shares during the period. Barclays PLC owned about 0.12% of ARS Pharmaceuticals worth $1,618,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. J.W. Cole Advisors Inc. increased its position in shares of ARS Pharmaceuticals by 10.8% during the 2nd quarter. J.W. Cole Advisors Inc. now owns 15,400 shares of the company’s stock valued at $131,000 after purchasing an additional 1,500 shares during the last quarter. nVerses Capital LLC bought a new position in ARS Pharmaceuticals in the 3rd quarter worth $30,000. Creative Planning lifted its position in ARS Pharmaceuticals by 7.0% during the third quarter. Creative Planning now owns 35,263 shares of the company’s stock valued at $511,000 after purchasing an additional 2,307 shares in the last quarter. HighTower Advisors LLC grew its holdings in ARS Pharmaceuticals by 18.2% during the third quarter. HighTower Advisors LLC now owns 28,310 shares of the company’s stock valued at $411,000 after purchasing an additional 4,369 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its position in ARS Pharmaceuticals by 151.7% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,419 shares of the company’s stock worth $63,000 after buying an additional 4,472 shares in the last quarter. 68.16% of the stock is currently owned by hedge funds and other institutional investors.

ARS Pharmaceuticals Stock Performance

Shares of SPRY stock opened at $10.79 on Friday. The stock has a 50 day moving average price of $13.91 and a 200 day moving average price of $12.51. ARS Pharmaceuticals, Inc. has a 52-week low of $5.19 and a 52-week high of $18.51. The firm has a market capitalization of $1.05 billion, a P/E ratio of -21.16 and a beta of 0.88.

Insiders Place Their Bets

In other news, insider Sarina Tanimoto sold 100,000 shares of the firm’s stock in a transaction on Tuesday, December 17th. The stock was sold at an average price of $11.67, for a total transaction of $1,167,000.00. Following the transaction, the insider now owns 1,098,499 shares in the company, valued at approximately $12,819,483.33. This trade represents a 8.34 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, major shareholder James E. Flynn sold 528,456 shares of ARS Pharmaceuticals stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $18.04, for a total value of $9,533,346.24. Following the completion of the sale, the insider now owns 5,274,735 shares of the company’s stock, valued at $95,156,219.40. The trade was a 9.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 1,258,058 shares of company stock worth $19,369,686 over the last quarter. Company insiders own 40.10% of the company’s stock.

Analyst Ratings Changes

SPRY has been the subject of several recent analyst reports. Leerink Partners upped their target price on shares of ARS Pharmaceuticals from $21.00 to $25.00 and gave the stock an “outperform” rating in a report on Friday, September 20th. Cantor Fitzgerald reissued an “overweight” rating and set a $30.00 price objective on shares of ARS Pharmaceuticals in a research note on Tuesday, October 8th. Finally, William Blair upgraded ARS Pharmaceuticals to a “strong-buy” rating in a research report on Friday, August 30th. Four research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Buy” and an average price target of $24.00.

ARS Pharmaceuticals Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.